• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Inventiva S.A.

    5/23/25 6:05:06 AM ET
    $IVA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IVA alert in real time by email
    6-K 1 f6k_052325.htm FORM 6-K
     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 6-K

    REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

    For the month of May 2025

    Commission File Number: 001-39374

    Inventiva S.A.
    (Translation of registrant's name into English)

    50 rue de Dijon
    21121 Daix France
    +33 3 80 44 75 00
    (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
    Form 20-F [ X ]      Form 40-F [   ]


    On May 23, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

    (c) Exhibit 99.1. Press release dated May 23, 2025


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

          Inventiva S.A.    
      (Registrant)
       
      
    Date: May 23, 2025     /s/ Frédéric Cren    
      Frédéric Cren
      Chief Executive Officer
      
    Get the next $IVA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IVA

    DatePrice TargetRatingAnalyst
    2/21/2025$10.00Buy
    TD Cowen
    11/12/2024$3.00Neutral
    UBS
    10/27/2023$12.00Buy
    Canaccord Genuity
    5/31/2023$11.00Buy
    ROTH MKM
    5/19/2023Sell → Buy
    Societe Generale
    3/17/2023$27.00Buy
    Stifel
    11/15/2022Buy → Sell
    Societe Generale
    11/22/2021$40.00 → $42.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $IVA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Inventiva Announces the Appointment of Renée Aguiar-Lucander to its Board of Directors

      Daix (France), New York City (New York, United States), June 10, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced the appointment of Renée Aguiar-Lucander to its Board of Directors. The appointment was approved by shareholders at the recent Company's Annual General Meeting. Mark Pruzanski, Chairman of Inventiva: "We are thrilled to welcome Renée to the Board at this pivotal moment in Inventiva's journey. Her exceptional track record in our industry speaks for itself and will be

      6/10/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva to Participate in the Upcoming Jefferies Global Healthcare Conference and UBS Spring Biotech Conference

      Daix (France), New York City (New York, United States), May 27, 2025 – Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today announced that the Company's Management will participate in two upcoming investor conferences in June 2025. Frédéric Cren, CEO and cofounder of Inventiva, will present a corporate overview during a fireside chat at the Jefferies Global Healthcare Conference which will take place in New York on June 4th at 10:30am ET.   The fireside chat will be webcast live and will be access

      5/27/25 4:00:00 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Inventiva reports 2025 First Quarter Financial Information¹

      Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ("MASH"), today reported financial information for the first quarter of 2025, including its cash, cash equivalents and revenues. Key Financial Results Cash, cash equivalents and deposits As of March 31, 2025, the Company's cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024. The decrease of €28.7 million is  

      5/23/25 2:30:00 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IVA
    SEC Filings

    See more
    • SEC Form SCHEDULE 13G filed by Inventiva S.A.

      SCHEDULE 13G - Inventiva S.A. (0001756594) (Subject)

      6/20/25 12:47:19 PM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/23/25 6:05:05 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Inventiva S.A.

      6-K - Inventiva S.A. (0001756594) (Filer)

      5/23/25 6:05:06 AM ET
      $IVA
      Biotechnology: Pharmaceutical Preparations
      Health Care